Disease/Condition
465 Clinical Trials
10+ Countries
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Database - Free Access to 465 Studies
Access comprehensive clinical trial information for Chronic Obstructive Pulmonary Disease (COPD) through Pure Global AI's free database. This collection includes 465 clinical trials across multiple phases including N/A, Phase 3, Phase 2. Currently, 28 trials are actively recruiting participants.
Research for Chronic Obstructive Pulmonary Disease (COPD) is being conducted in United States of America, United Kingdom, China and 7+ other countries. Leading sponsors include AstraZeneca and Novartis Pharmaceuticals. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Free Database
Powered by Pure Global AI
840K+ Global Trials
Updated Daily
By Phase
N/A
261Phase 3
67Phase 2
51Phase 4
37Not Applicable
20By Status
Completed
348Unknown
28Recruiting
28Not yet recruit...
20Terminated
13Top Countries
United States of America51
United Kingdom25
China20
Australia17
Germany16
Top Sponsors
AstraZeneca49
Novartis Pharmaceu...25
Novartis Pharma Se...18
AstraZeneca AB15
GlaxoSmithKline Re...13
Recent Trials
Latest clinical trials for Chronic Obstructive Pulmonary Disease (COPD)
PHRR230616-005752
Phase 3
Suspended
PROSPERO
AstraZeneca ABPhilippines
2017-001593-42
A 24-week randomized, controlled, multicenter, open-label study to
Novartis Pharma AG
PHRR211202-004106
Phase 2
Terminated
A 12-week randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled CSJ117 in adults with Chronic Obstructive Pulmonary Disease (COPD)
Novartis Healthcare Philippine...Argentina;Australia;Belgium;Canada;Czech;Republic;France;Hungary;India;Israel;Japan;Mexico;Philippin
NCT06376994
Phase 3
Not yet recr...
Multi-Center Clean Air Randomized Controlled Trial in COPD
JHSPH Center for Clinical Tria...United States of America
NCT06368427
Not yet recr...
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
AstraZeneca
NCT06321731
Not yet recr...
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.
AstraZeneca
NCT06265623
Not yet recr...
Intermittent Hypoxemia, Lung Function Decline, Morbidity, and Mortality in COPD (PROSA Study).
Universitätsklinikum Hamburg-E...Germany
NCT06040086
Phase 3
Recruiting
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
AstraZenecaArgentina,Belgium,Brazil,Canada,China,France,Germany,Greece,Hungary,Ireland,Italy,Japan,Malaysia,Net
RBR-6m9pwb7
Recruiting
Efficacy of behavioral change on cardiovascular system, physical activity level and functionality after exacerbation of Chronic Obstructive Pulmonary Disease
Universidade Federal de São Ca...Brazil
NCT05888597
Phase 2
Not yet recr...
Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease
Region SkaneSweden
NCT05838703
Phase 2
Withdrawn
Tiotropium Handihaler vs. Tiotropium Respimat in COPD
Duke University
RBR-9wwp8kp
Completed
Effect of Physical Exercise in older adults with Pulmonary Disease from Manizales
Universidad Autónoma de Maniza...Colombia
jRCT2031220659
Recruiting
Untitled Trial
Astrazeneca K.KArgentina;Belgium;Bulgaria;Canada;Czech;Denmark;Finland;Hungary;India;Mexico;Netherlands;Norway;Port
NCT05742802
Phase 3
Recruiting
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
AstraZenecaArgentina,Australia,Belgium,Brazil,Bulgaria,Canada,Colombia,Czech,Denmark,Finland,Germany,Greece,Hun
NCT05661435
Withdrawn
Utility of Remote Lung Auscultation in Transitions of Care After Pulmonary Exacerbations of COPD
Strados Labs, Inc.United States of America
2022-002441-18
Ongoing
A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca AB
NCT05595642
Phase 2/3
Recruiting
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
Hoffmann-La RocheUnited States of America
NCT05573464
Phase 3
Recruiting
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
AstraZenecaArgentina,Bulgaria,Canada,Germany,Mexico,Poland,Turkey,United Kingdom,United States of America
NCT05492877
Phase 2
Not yet recr...
An Efficacy and Safety Study of AZD4831 (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
AstraZeneca
2019-005005-43
Ongoing
Ferinject in Addition to pulmonary rehabilitation in patients with COPD and iron deficiency to improve Exercise tolerance (FACE II study)
Consorci Mar Parc de Salut de ...
About Chronic Obstructive Pulmonary Disease (COPD) Research
Pure Global AI provides free access to 465 clinical trials studying Chronic Obstructive Pulmonary Disease (COPD), aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include AstraZeneca, Novartis Pharmaceuticals, Novartis Pharma Services AG, among others.
Quick Facts
Total Trials465
Countries10+
Sponsors10+
Recruiting28